Lumos Diagnostics secures FDA milestone, $25M funding
Lumos Diagnostics (ASX:LDX) announced a US market expansion triggered by the US FDA granting a CLIA waiver for its flagship point-of-care test, FebriDx.
Lumos Diagnostics (ASX:LDX) announced a US market expansion triggered by the US FDA granting a CLIA waiver for its flagship point-of-care test, FebriDx.
4DMedical (ASX:4DX) secured CE Mark clearance for its pioneering CT:VQ software.
Duratec (ASX:DUR) announced a milestone with the awarding of a multi-million-dollar service contract in Papua New Guinea.
Nicolás Maduro appeared in a Manhattan federal court Thursday as the US pushes forward with a broad drug-trafficking and narco-terrorism conspiracy case against the ousted Venezuelan leader. Bloomberg's Christina Ruffini reports from New York.
RoboSense CEO Mark Qiu talks about the key takeaways of their first-ever profitable quarter since 2014. He explains how the shift from analog to digital LiDAR will lift the company's performance and is a great cost advantage
InFocus Group (ASX:IFG) announced the completion of Codexa, a sweepstakes casino platform developed by its internal division, IFG iGaming.
Lodestar Minerals (ASX:LSR), the Western Australian gold and base metals explorer, has appointed Coraline Blaud as its new CEO.
Global Laser Enrichment secured preliminary approval for a comprehensive US$98.9 million incentives package.
Federal Reserve Governor Stephen Miran says the Fed can shrink its balance sheet meaningfully from current levels but cautioned the process would likely take years and require several steps. He speaks during an event at the Economic Club of Miami.
BlueScope Steel (ASX:BSL) announced an escalation in its program to unlock capital from its extensive 1,200-hectare surplus industrial land portfolio.
Federal Reserve Governor Lisa Cook says the Iran war has shifted the balance of risks for now, leaving inflation as a bigger concern for policymakers than employment. She speaks during an event in New Haven, Connecticut.
Radiopharm Theranostics (ASX:RAD) has dosed the first patient in its Phase 1 clinical trial of RAD 402.
Tem um segundo para um cookie? 🍪Os cookies essenciais mantêm a Grafa funcionando bem. Alguns opcionais nos ajudam a ver o que está funcionando para melhorarmos. Você tem o controle — pode mudar de ideia quando quiser. Política de cookies · Política de privacidade